Emblem Corp EMMBF

Buy recomendation

[cabz]

FP says Canaccord begins coverage of Aphria, others 2017-03-14 07:44 ET - In the News See In the News (C-APH) Aphria Inc The Financial Post reports in its Tuesday edition that Canaccord says the company that will wind up the winner in Canada's budding marijuana industry already exists among the handful of licensed medical marijuana producers. The Post's Sunny Freeman writes that Canaccord launched coverage of marijuana companies Monday. Analysts Neil Maruoka and Matt Bottomley say, "We believe cannabis to be one of the most exciting areas of investment to emerge in recent years." Among the six marijuana firms the analysts now cover, they believe Aurora Cannabis is the best pick due to its low-cost production and funded capacity. They believe that at $2.42 per share provides the most attractive return. They also say OrganiGram provides investors with the greatest upside if it can overcome its reputational challenges. The other two stock picks in its speculative buy category are Emblem, which is supported by its position as a purely medical play, and Supreme Pharmaceuticals, which it believes is undervalued as it awaits its sales licence. They see current market leaders Canopy Growth and Aphria as fairly valued. They say, "We believe that existing LPs already have a substantial head start over unlicensed peers." 2017 Canjex Publishing Ltd. All rights reserved.